Target Institutions Ornim targets large hospitals, ICUs, and surgical suites where perfusion monitoring is critical. Highlight CerOx's simultaneous non invasive measurement of blood flow and oxygen saturation and the FDA approved c-FLOW for CBF, emphasizing faster clinical decisions and potential cost reductions in patient care.

Strategic Partnerships Strategic partnerships with large distributors and systems, leveraging GE Healthcare's investment in Ornim to open doors in major markets. Pursue co marketing, distribution agreements, or channel partnerships to scale adoption and credibility in hospital procurement processes.

Market Growth Rising demand for non invasive perfusion monitoring creates a receptive market. UTLight technology differentiates from standard NIRS by analyzing light speckle signals, enabling more reliable perfusion and tissue oxygenation measurements and stronger value proposition for clinicians and payers.

Global Expansion Global expansion with limited headcount benefits from distributor networks and regional regulatory readiness. Prioritize regulatory clearance (FDA and CE marking) and reimbursement strategies, plus targeted clinical pilots to demonstrate ROI and patient outcomes across regions.

IP Advantage Intellectual property moat with multiple worldwide patents supports licensing and co development opportunities. Engage potential licensees among medical device manufacturers and research centers to accelerate scale while protecting competitive advantage.